Gr431 (ATCC® HB-8575)

Organism: human (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  /  Disease: Cancer

Permits and Restrictions

View Permits

Organism human (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease Cancer
Derivation
Lymphocytes were obtained from the regional lymph nodes of a patient who had breast cancer.
Lymphocytes were fused with NS-1 myeloma cells.
Clinical Data
Lymphocytes were obtained from the regional lymph nodes of a patient who had breast cancer.
Genes Expressed
immunoglobulin; monoclonal antibody; against an intracellular antigen expressed in human malignant cells (cancer, tumor)
Comments
Lymphocytes were obtained from the regional lymph nodes of a patient who had breast cancer.
Lymphocytes were fused with NS-1 myeloma cells.
Complete Growth Medium RPMI 1640 medium with 0.1 mM hypoxanthine and 0.016 mM thymidine, 90%; fetal bovine serum, 10%
Complete Growth Medium
Culture Medium: RPMI medium 1640 with 0.1 mM hypoxanthine, 0.016 mM thymidine,
90%; fetal bovine serum, 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
Culture medium, 90%; DMSO, 10%
Isotype IgM
Name of Depositor Sloan-Kettering Institute for Cancer Research
References

Thomson TM, et al. Human monoclonal antibodies to cell surface antigens. US Patent 4,695,538 dated Sep 22 1987

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Thomson TM, et al. Human monoclonal antibodies to cell surface antigens. US Patent 4,695,538 dated Sep 22 1987